{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:28Z","timestamp":1761587008324,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.intimp.2021.108214","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:47:36Z","timestamp":1633481256000},"page":"108214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PB","title":["Serology-based therapeutic strategy in SARS-CoV-2-infected patients"],"prefix":"10.1016","volume":"101","author":[{"given":"Ricardo","family":"Garcia-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Farf\u00e1n-Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Ruiz-de-Lobera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Anton-Remirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"N\u00e1jera Irazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Lisa Cat\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Oteo-Revuelta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.108214_b0005","article-title":"Recovery collaborative group. Dexamethasone in hospitalized patients with COVID19- preliminary report","author":"Horby","year":"2020","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.108214_b0010","unstructured":"National Institutes of Health. The COVID-19 Treatment Guidelines Pane\u013as Statement on the emergency use authorization of convalescent plasma for the treatment of covid-19. Accessed at www.covid19treatmentguidelines.nih.gov\/statement-on-convalescent-plasma-eua on 7 September 2020."},{"key":"10.1016\/j.intimp.2021.108214_b0015","doi-asserted-by":"crossref","unstructured":"C. Salvarani, G. Dolci, M.D. Masari, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID19 Pneumonia. A Randomized Clinical Trial. JAMA Intern Med. 181(1) (2021) 24\u201331. Doi:10.1001\/jamaintermed.2020.6615.","DOI":"10.1001\/jamainternmed.2020.6615"},{"key":"10.1016\/j.intimp.2021.108214_b0020","unstructured":"A. Bhimraj, R.L. Morgan, A.H. Shumaker, et al, Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID19. Infections Diseases Society of America 2021. Version 4.3.0. Available at https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"issue":"19","key":"10.1016\/j.intimp.2021.108214_b0025","article-title":"Antibody therapies for the prevention and treatment of viral infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.intimp.2021.108214_b0030","unstructured":"R.R. Rich, T.A. Fleisher, W.T. Shearer et al., 2019. Clinical immunology. Principles and practice. 5th ed. Elseviers Saunders 860-873, 716-727."},{"issue":"5","key":"10.1016\/j.intimp.2021.108214_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.intimp.2021.108214_b0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2021.108214_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the Cumulative Illness Rating Scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J. Am. Geriatric Soc."},{"key":"10.1016\/j.intimp.2021.108214_b0050","doi-asserted-by":"crossref","first-page":"m606","DOI":"10.1136\/bmj.m606","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan","volume":"368","author":"Xu","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2021.108214_b0055","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal Characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","volume":"55","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.intimp.2021.108214_b0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00277-020-04103-5","article-title":"Hematological findings in coronavirus disease 2019: Indications of progression of disease","volume":"99","author":"Liu","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2021.108214_b0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12026-015-8747-9","article-title":"Follicular lymphoma: in vitro effects of combining lymphocyte-activated killer (LAK) cell induced cytotoxicity and rituximab- and Obinutuzumab-dependent cellular cytotoxicity (ADCC) activity","volume":"64","author":"Garc\u00eda-Mu\u00f1oz","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2021.108214_b0070","doi-asserted-by":"crossref","unstructured":"C. Freeman, F. Morschauser, L. Sehn, M. Dixon, R. Houghton, T. Lamy, et al., Cytokine release in patients with Obinutuzumab and possible relationship with infusion related reactions, (2015) Blood 126(24):2646-2649 Doi 10.1182\/blood-2015-09-670802.","DOI":"10.1182\/blood-2015-09-670802"},{"issue":"6","key":"10.1016\/j.intimp.2021.108214_b0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2017-0147","article-title":"Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia","volume":"10","author":"Garc\u00eda-Mu\u00f1oz","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2021.108214_b0080","doi-asserted-by":"crossref","unstructured":"R. Garc\u00eda-Mu\u00f1oz, M.J. Najera, J. Feliu, J. Anton-Remirez, Ramalle-G\u00f3mara, R. Marin-Gorricho, R. Peralta, et al., Battle of Thermopylae: 300 Spartans (natural killer cells plus Obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxe\u015b army. (2019) Future Sci OA. 2019;5 (10):FSO425. Doi: 10.2144\/fsoa-2019-0064.","DOI":"10.2144\/fsoa-2019-0064"},{"key":"10.1016\/j.intimp.2021.108214_b0085","doi-asserted-by":"crossref","unstructured":"R. Garc\u00eda-Mu\u00f1oz, J. Feliu, J. Anton-Remirez, L. Metola, E. Sosa-Campos, M.P. Sanz, et al., Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19). (2021). Ir. J. Med. Sci. 2, 1\u20133. Doi: 10.1007\/s11845-021-02701-4.","DOI":"10.1007\/s11845-021-02701-4"},{"key":"10.1016\/j.intimp.2021.108214_b0090","unstructured":"RECOVERY Collaborative group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomized controlled, open-label, plataform trial. (2021) Lancet:397:2049-59."},{"issue":"8","key":"10.1016\/j.intimp.2021.108214_b0095","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/trf.16525","article-title":"Use of convalescent plasma in COVID-19 patients with immunosuppression","volume":"61","author":"Senefeld","year":"2021","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.intimp.2021.108214_b0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2021.108214_b0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from COVID19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl. J. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692100850X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692100850X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:36:49Z","timestamp":1761586609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692100850X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":21,"alternative-id":["S156757692100850X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108214","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serology-based therapeutic strategy in SARS-CoV-2-infected patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108214"}}